Keywords
Dengue hemorrhagic fever
Severe dengue
Hospitalization
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the prevalence profile of dengue hemorrhagic fever in the Brazilian Midwest between 2019 and 2025, as well as possible related factors. Methods: This is an ecological study, conducted between 2024 and 2025, using DATASUS with the following descriptors: year of notification, month of notification, region of notification, age group, race, sex, final classification, evolution, serological test (IgM) Dengue, viral isolation test, RT-PCR test, serotype, and hospitalization. Results: A reduction in reported cases of classic and hemorrhagic dengue fever was observed during the years of the COVID-19 pandemic (2020-2021), attributed to underreporting, followed by a significant increase in 2022 and a peak in 2024. Most cases involved adults and the elderly, especially males and those of mixed race, and the main circulating viral serotypes during the period were DENV-1 and DENV-2. In 2025, there was a significant decrease in cases, possibly related to the introduction of the Qdenga® vaccine. Conclusion: The findings reinforce the importance of vaccination and continuous epidemiological surveillance, especially in highly endemic regions such as the Midwest.
References
ALMEIDA LS, et al. Impactos na saúde urbana: saneamento, arboviroses e vulnerabilidade social. Revista Ciência & Saúde Coletiva, 2020; 25(10): 3857–3868.
BEZERRA JMT, et al. Entry of dengue virus serotypes and their geographic distribution in Brazilian federative units: a systematic review. Revista Brasileira de Epidemiologia, 2021; 24.
BISWAL S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. Revista New England Journal of Medicine, 2019; 381(21): 2009–2019.
BORRE F, et al. Impact of the COVID-19 Pandemic on Infectious Diseases in Brazil: A Case Study on Dengue Infections. Revista Epidemiologia (Basileia), 2022; 3(1): 97-115.
BRASIL. MINISTÉRIO DA SAÚDE. Fundação Nacional de Saúde (FUNASA). Guia de Vigilância Epidemiológica. Brasília: Ministério da Saúde, 2002. Disponível em: https ://bvsms.saude.gov.br/bvs/pub licacoes/funasa/guia_vig_epi_vol_l.pdf.
BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde e Ambiente. Departamento de Doenças Transmissíveis. Dengue: diagnóstico e manejo clínico. Brasília: Ministério da Saúde, 2024. Disponível em: https ://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/dengue/den gue-diagnostico-e-manejo-clinico-adulto-e-crianca.
BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Dengue: diagnóstico e manejo clínico adulto e criança. Brasília: Ministério da Saúde, 2013. Disponível em: https ://bvsms.saude.gov.br/bvs/publicacoes/dengue_diagnostico_manejo _clinico_adulto.pdf.
BRITO PVMB, et al. Epidemiologia das internações por dengue no Brasil nos últimos 10 anos (2014-2024). Revista Brazilian Journal od Implantology and Health Sciences. 2025; 7(2): 1518-1530.
CAO Y, et al. Epidemiological Trends and Age–Period–Cohort Effects on Dengue Incidence Across High-Risk Regions from 1992 to 2021. Tropical Medicine and Infectious Disease. 2025; 10(6): 173.
CARDIM LL, et al. Socioeconomic markers of dengue mortality in the 100 Million Brazilian Cohort (2007–2018): A nationwide registry-based cohort study. Revista PLoS Neglected Tropical Diseases. 2025; 19(11): 13660.
DONATELI CP e CAMPOS FC. Visualização de dados de vigilância das arboviroses urbanas transmitidas pelo Aedes aegypti em Minas Gerais, Brasil Revista Journal of Information Systems and Technology Management, 2023; 20: 1775-1807.
GRUBAUGH ND, et al. Dengue outbreak caused by multiple virus serotypes and lineages, Colombia, 2023-2024. Emerging Infectious Diseases, 2024; 30(11): 2391-5.
GRUPTA A, et al. Prevalence of Dengue Serotypes and Its Correlation With the Laboratory Profile at a Tertiary Care Hospital in Northwestern India. Revista Cureus. 2021; 13(5).
GURGEL-GONÇALVES R, et al. The greatest Dengue epidemic in Brazil: Surveillance, Prevention and Control. Revista da Sociedade Brasileira de Medicina Tropical. 2024; 57.
GUZMÁN MG, HARRIS E. Dengue. Revista Lancet, 2015; 385(9966): 453-465.
NUNES PCG, et al. 30 years of dengue fatal cases in Brazil: a laboratorial-based investigation of 1047 cases. Revista BMC Infectious Diseases, 2018; 18(1).
OLIVEIRA AC, et al. Febre hemorrágica da dengue: aspectos epidemiológicos e econômicos no Brasil. Revista Unimontes Científica, 2021; 23(2): 1-17.
RANZANI OT, et al. Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study. Revista The Lancet Infectious Diseases, 2025.
RODRIGUES MZet al. Perfil epidemiológico da dengue no Centro-Oeste: da endemia à epidemia. Revista The Brazilian Journal of Infectious Diseases, 2024; 28(1).
ROTHMAN AL. Immunity to dengue vírus: a tale of original antigenic sin and tropical cytokine storms. Revista Nature Immunology, 2011; 11: 532-543.
SAMPAIO BR, et al. Acompanhamento da evolução da taxa de óbito por febre hemorrágica pelo vírus da dengue no Brasil, durante o período de 2018 e 2023. Revista The Brazilian Journal of Infectious Diseases, 2023; 27(1).
VICENTE CR, et al. Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil. Revista BMC Infectious Diseases, 2016; 16(320).